Evolus, Inc. (EOLS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US30052C1071
Evolus, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 297.18 m USD |
| Gross profit | 197.11 m USD |
| Operating income | -32.66 m USD |
| EBIT | -31.27 m USD |
| Net income | -51.64 m USD |
| Diluted EPS – continuing operations | -0.80 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
More stocks
- China Chippacking Technology Co. Ltd. A (688216.SS)
- Shanghai Sheng Jian Environment Technology Co Ltd (603324.SS)
- Tronox Holdings plc (TROX)
- Blue Label Telecoms Ltd (BLU.JO)
- Euroseas Ltd (ESEA)
- Ballard Power Systems Inc (BLDP.TO)
- Kaufman Et Broad (KOF.PA)
- PRA GROUP INC (PRAA)
- Philoptics Co., Ltd. (161580.KQ)
- Stemmer Imaging (S9I.HM)
- Hvm, Co.,Ltd. (295310.KQ)
- Pioneer Bancorp, Inc./MD (PBFS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.